Latus Launches with State-of-the-Art Gene Therapy Development Technologies, Two Lead Product Candidates, and an Initial $54 Million in Series A Financing
Series A financing co-led by 8VC and DCVC Bio May 02, 2024 01:00 PM Pacific Daylight Time PHILADELPHIA–(BUSINESS WIRE)–Latus Bio, Inc. (“Latus”), a biotechnology company developing novel gene therapy candidates for disorders of the central…